ClinicalTrials.gg
CompletedNCT06549114Updated Oct 19, 2026

Leniolisib for Immune Dysregulation in PIDs

A Phase 2 interventional study of Leniolisib in Primary Immunodeficiency Disorders (PIDs), sponsored by Pharming Technologies B.V.. Completed at 1 site in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Pharming Technologies B.V. (part of Pharming Group N.V.) · Phase 2, Interventional, and Treatment

Updated Oct 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies in Primary Immunodeficiency Diseases with a site in United States — 25 open to participants now, 35 under way, 4 of them phase 3. Primary Immunodeficiency Diseases · United States.

Enrollment
63rd of 75
13 · median 40
Started
2024
with 3 others
Phase 2
12 of 108
7 open now
Registered
103rd of 108
by date

Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, this one is the 63rd largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 in phase 2, and was the 103rd registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

25 of the 108 studies in Primary Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Primary Immunodeficiency Diseases with a site in United States, or all of them as a file.
02

Study summary

This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.

Read the detailed description

Patients ages 12-75 diagnosed with genetically defined PID disorders linked to PI3K signaling. This includes disorders caused by pathogenic variants in SOCS1, PTEN, CTLA4, NFKB1 (variants leading to NFKB pathway activation), FAS (germline or somatic), or RAS-associated leukoproliferative disorder caused by somatic variants in NRAS or KRAS (not juvenile myelomonocytic leukemia [JMML]). All subjects participating will receive leniolisib film-coated tablets (FCTs) with a planned dose regimen consisting of a starting dose of 10 mg twice daily (BID) for 4 weeks, followed by 30 mg BID for 4 weeks, and then 70 mg BID for 12 weeks. Leniolisib dose increase at the individual subject level will occur if no safety or tolerability issues have been identified by the Investigator that precludes the planned dose escalation.

Subjects not continuing leniolisib treatment outside of the current protocol will be followed up, with the EOS visit planned to occur approximately 28 days after last dose of leniolisib.

03

Conditions studied

  • Primary Immunodeficiency Disorders (PIDs)
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects 12 to 75 years of age.
  2. Diagnosed with a PID due to disease-causing pathogenic or likely pathogenic variant(s) in the following genes: SOCS1, PTEN, CTLA4, NFKB1 (only those variants leading to NFKB pathway activation), or FAS (germline or somatic), or diagnosed with RAS associated leukoproliferative disorder (and not juvenile myelomonocytic leukemia [JMML]) due to somatic variants in NRAS or KRAS.
  3. Subjects must have 1 or more of the following:

    • One or more blood cytopenias related to the underlying PID defined as \<10 g/dL, count \<100,000/µL, or \<1000/µL
    • Splenomegaly evident by CT imaging with craniocaudal spleen measurement >10 cm
    • Lymphadenopathy evident by CT imaging with at least 1 measurable index lymph node (long axis >1.5 cm) as per Cheson methodology
    • GLILD or other PID-related ILD with quantifiable CT chest imaging findings evident on baseline CT scan
  4. At screening, vital signs.

    • Systolic blood pressure 80-139 mm Hg
    • Diastolic blood pressure 50-89 mm Hg
    • Pulse rate 50-110 bpm
    • Oxygen saturation 93-100%
  5. Subjects or their legal representatives (for subjects under the age of 18 years) must be able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Subject has had a successful hematopoietic stem-cell transplant ().
  2. Previous or concurrent use of medication, such as:

    • Use of an mTOR inhibitor or a PI3Kδ inhibitor within 3 weeks prior to first dosing .
    • Rituximab or other B-cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months prior to first dosing.
    • Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other JAK inhibitors within 3 weeks prior to first dosing.
    • above 25 mg prednisone or equivalent per day within 2 weeks prior to first dosing.
    • Other immunosuppressive agents expected to have a significant impact on immune cell number or function.
    • Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months prior to first dosing.
  3. Subject is receiving concurrent treatment with another therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer) prior to first dosing.
  4. History of to the study drug or to drugs of similar chemical classes.
  5. Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme P450 .
  6. Current use of medications that act as BCRP, OATP1B1, and OATP1B3 substrates.
  7. Subject has a history or current (ECG) abnormalities indicating a significant risk of safety for subjects participating in the study
  8. History of acquired immunodeficiency diseases, including a positive test result at screening.
  9. Uncontrolled chronic or recurrent infectious disease (except those considered to be characteristic of a PID) or evidence of tuberculosis infection
  10. Any surgical or medical condition which may jeopardize the subject in case of participation in the study, or might significantly alter the absorption, distribution, metabolism, or excretion of drugs.
  11. A positive surface antigen, positive hepatitis B PCR, positive PCR, or positive hepatitis C antibody result at screening.
  12. Administration of starting from 6 weeks before first dose of study medication.
  13. Subject has a previous diagnosis of lymphoma within 1 year of the first dose of study medication.
  14. Subject has a history of (except lymphoma) within 3 years before the first dose of study medication, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
  15. Subject has uncontrolled post-transplant lymphoproliferative disease (PTLD)-like EBV related lymphoproliferative disease.
  16. Donation or loss of 400 mL or more of blood within 8 weeks before the first dose.
  17. Subject has had major surgery requiring hospitalization or radiotherapy within 4 weeks prior to the first dose or has a planned or expected major surgical procedure during the study period.
  18. Pregnant or nursing (lactating) individuals,.
  19. Individuals of , unless they are using highly effective methods of .
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Leniolisib

    All subjects participating will receive Leniolisib film-coated tablets (FCTs) at a starting dose of 10 mg BID for 4 weeks, followed by 30 mg BID for 4 weeks, and then 70 mg BID for 12 weeks.

    Drug: Leniolisib

Interventions

  • The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).

    Also known as: Joenja

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs)

    • To assess the number of AEs/SAEs and number of participants with AEs/SAEs

    Time frame: From Baseline to the end of 20 weeks of Treatment

Secondary outcomes

  1. To assess the PK of leniolisib in PID disorders linked to PI3K

    • PK parameters for leniolisib defined by Cmax

    Time frame: From Baseline to the end of 20 weeks of Treatment

  2. To assess the PK of leniolisib in PID disorders linked to PI3K

    • PK parameters for leniolisib defined by Tmax

    Time frame: From Baseline to the end of 20 weeks of Treatment

  3. To assess the PK of leniolisib in PID disorders linked to PI3K

    • PK parameters for leniolisib defined by t1/2

    Time frame: From Baseline to the end of 20 weeks of Treatment

  4. To assess the PK of leniolisib in PID disorders linked to PI3K

    • PK parameters for leniolisib defined by AUC (0-t)

    Time frame: From Baseline to the end of 20 weeks of Treatment

  5. To assess the impact of leniolisib on lymphocyte PI3K/AKT/mTOR pathway activity in PID disorders linked to PI3K

    • Percent change in pAKT and/or pS6 in B cells and/or T cells, under resting and stimulated conditions, at different dose levels of leniolisib relative to baseline pAKT/pS6 levels, as feasible

    Time frame: From Baseline to the end of 20 weeks of Treatment

  6. To assess the impact of leniolisib on hemoglobin counts in PID disorders linked to PI3K

    • Hemoglobin over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  7. To assess the impact of leniolisib on platelet counts in PID disorders linked to PI3K

    • Platelet count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  8. To assess the impact of leniolisib on absolute neutrophil counts in PID disorders linked to PI3K

    • Absolute neutrophil count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  9. To assess the clinical efficacy of leniolisib on PID-related ILD in PID disorders linked to PI3K

    • Change in CT evidence of GLILD or other PID-related ILD evaluated using Hartmann scoring methodology

    Time frame: From Baseline to the end of 20 weeks of Treatment

  10. To assess the clinical efficacy of leniolisib on PFTs in PID disorders linked to PI3K

    • Change in forced expiratory volume 1 (FEV1)

    Time frame: From Baseline to the end of 20 weeks of Treatment

  11. To assess the clinical efficacy of leniolisib on PFTs in PID disorders linked to PI3K

    • Change in forced vital capacity (FVC)

    Time frame: From Baseline to the end of 20 weeks of Treatment

  12. To assess the clinical efficacy of leniolisib on PFTs in PID disorders linked to PI3K

    • Change in total lung capacity (TLC)

    Time frame: From Baseline to the end of 20 weeks of Treatment

  13. To assess the clinical efficacy of leniolisib on PFTs in PID disorders linked to PI3K

    • Change in diffusing capacity (DLCO)

    Time frame: From Baseline to the end of 20 weeks of Treatment

  14. To assess the clinical efficacy of leniolisib on lymphoproliferation in PID disorders linked to PI3K

    * Percent change from baseline in lymphadenopathy measured as the sum of product of diameters (SPD) in the index lesions selected per the Cheson methodology * Percent change from baseline in lymphadenopathy measured as SPD of measurable non-index lesions selected as per the Cheson methodology

    Time frame: From Baseline to the end of 20 weeks of Treatment

  15. To assess the clinical efficacy of leniolisib on splenomegaly in PID disorders linked to PI3K

    • Percent change from baseline in splenomegaly measured by three-dimensional (3D) volume and bi-dimensional (2D) size of spleen

    Time frame: From Baseline to the end of 20 weeks of Treatment

  16. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • White blood cell count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  17. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • Absolute monocyte count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  18. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • Absolute lymphocyte count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  19. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • Absolute eosinophil count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  20. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • Absolute basophil count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  21. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • CD4+ T cell count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  22. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • CD8+ T cell count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  23. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • Natural killer (NK) cell count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  24. To assess the impact of leniolisib on white blood cell counts in PID disorders linked to PI3K

    • B cell count over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  25. To assess the impact of leniolisib on B cell and T cell phenotypic populations of interest in PID disorders linked to PI3K

    • Percentages of naïve B cells, CD21lo B cells and T regulatory cells over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

  26. To examine levels of CXCL13 and soluble IL-2Rα and assess the impact of leniolisib in PID disorders linked to PI3K

    * Levels of CXCL13 over time * Levels of soluble IL-2Rα over time

    Time frame: From Baseline to the end of 20 weeks of Treatment

07

Study locations

1 site
  • National Institute of Health
    Bethesda, Maryland 20892, United States
08

References and documents

Publications

  • Hassan C, Ponstein Y, Hanssen R, Thorneloe KS, Marsh RA, Rao VK. Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome. J Hum Immun. 2025 Nov 17;2(1):e20250125. doi: 10.70962/jhi.20250125. eCollection 2026 Jan 5. PubMed 41608120 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Jun 2026, 20 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Nov 2026 → Jun 2026 and completion Nov 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Aug 12, 2024
StartActual
Oct 21, 2024
Primary completionActual
Jun 23, 2026was Nov 2026
CompletionActual
Jun 23, 2026was Nov 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 19, 2026
Primary completion
Nov 2026→Jun 23, 2026 (actual)
Oct 19, 2026
Study completion
Nov 2026→Jun 23, 2026 (actual)
Oct 19, 2026
Enrollment
12 (estimated)→13 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Completed
    Primary completion Nov 2026→Jun 23, 2026 (now actual)
    Study completion Nov 2026→Jun 23, 2026 (now actual)
    Enrollment 12 (estimated)→13 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06549114
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Oct 21, 2024
Primary completion
Jun 23, 2026
Completion
Jun 23, 2026
Last update
Oct 19, 2026

Study contacts

Gulbu Uzel, M.D.
principal investigator · National Institutes of Health (NIH)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leniolisib

Start the discussion